Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
– Initial Results from Kite-753, Optimized with Novel Manufacturing Process That Preserves T-Cell Fitness, Show High Complete Response Rate and Favorable Safety... Read more.
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility,... Read more.
Orca Bio Presents New Clinical Data on Orca-T® in Older Patients Using Reduced Intensity Conditioning Plus New Analyses from the Precision-T Phase 3 Study at the 67th ASH Annual Meeting
Patients aged 60-75 treated with Orca-T and a reduced intensity conditioning regimen (RIC) experienced low incidence of acute and chronic GvHD with low rates of... Read more.
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients with... Read more.
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen... Read more.
NMDP℠ Demonstrates Scientific Leadership in Expanding Patient Access to Lifesaving Cell Therapy at ASH 2025
New results from the Phase II ACCESS trial represent a significant milestone in solving one of transplant medicine’s biggest challenges: finding a donor for every... Read more.
ReAlta Announces Promising Phase 2 Data Demonstrating Rapid Clinical Responses and Target Engagement in Steroid-Refractory Acute GvHD at the ASH 2025 Annual Meeting
Pegtarazimod demonstrates significant clinical improvement and reduction in inflammatory markers in patients with lower gastrointestinal acute GvHD NORFOLK, Va.–(BUSINESS... Read more.
Genetix Participates in the American Society of Hematology’s (ASH) Exclusive Press Program & Shares Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation
Data presented was selected for ASH’s exclusive program to highlight the most impactful research submitted for this year’s meeting Real-world data reinforces... Read more.
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
– Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the... Read more.
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies
TENGCHONG, China–(BUSINESS WIRE)–#AI–The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading... Read more.